Profile

Cover photo
Advaxis, Inc.
27 followers|11,864 views
AboutPostsPhotosYouTube

Stream

Advaxis, Inc.

Shared publicly  - 
 
Happy to announce that Advaxis’s president & CEO, Dan O'Connor, was recognized as the 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey. Take a look at the full announcement here: http://bit.ly/1BRbETN
PRINCETON, N.J., June 29, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its president and chief executive officer, Daniel O'Connor was selected as a winner in the 2015 Ernst & Young (EY) ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis, Inc. has been selected for inclusion in the Russell Global and Russell 3000 Indexes, according to a preliminary list of additions posted on June 12. Read the details here: http://bit.ly/1LpA0aC
PRINCETON, N.J., June 22, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the company will be added to the Russell Global and Russell 3000® Indexes. This inclusion will become effective upon the close of ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis submits Special Protocol Assessment request to FDA for Ph 3 study of ADXS-HPV in cervical cancer http://prn.to/1J3kAIy
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis received FDA clearance of its Investigational New Drug application to conduct a Phase 2 study of ADXS-HPV and Incyte's epacadostat for the treatment of HPV-associated early stage cervical cancer. "The FDA clearance of the ADXS-HPV plus epacadostat IND for HPV-associated early stage cervical cancer adds to Advaxis's rapidly advancing pipeline in cervical cancer," said CEO Dan O'Connor. http://bit.ly/1JjP6Mk
PRINCETON, N.J., June 1, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to conduct ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. (SRNE) to evaluate combinations of Advaxis's Lm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento's fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Click to read the full press release: http://bit.ly/1HpRRtU
PRINCETON, N.J. and SAN DIEGO, May 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis, Inc. (ADXS) has announced the closing of its latest public offering. http://bit.ly/1IL516s
PRINCETON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) a clinical-stage cancer immunotherapy company, today announced the closing of its previously announced underwritten public offering of 2800000 shares of its common stock at a public offering price of $19.00 per share.
1
Add a comment...
Have them in circles
27 people
Calvin Nokes's profile photo
Jeff Anlauf's profile photo
Giovanna Beeney's profile photo
David Miller's profile photo
Rick Vandewaa's profile photo
Jason Ian Hector's profile photo
Bettina Lau's profile photo
jim dooley's profile photo
Brad Loncar's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Provides 2015 Half-Year Review and Outlook. Take a look at the full announcement: http://bit.ly/1FCU0y8
PRINCETON, N.J., June 25, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today will hold a business update conference call at 8:30 a.m. ET highlighting year-to-date accomplishments and key near-term goals.
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
On June 25th, Advaxis, Inc. (ADXS) will hold a business update conference call. Take a look at the full announcement here: http://bit.ly/1BsE2vn
PRINCETON, N.J., June 19, 2015 /PRNewswire/ -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announces that its management team will host a corporate business update conference call and webcast to review recent accomplishments and key ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
On  Saturday, June 6, positive results from an ongoing clinical study of ADXS-HER2 in canine osteosarcoma (OSA) were presented at the American College of Veterinary Internal Medicine (ACVIM) Forum in Indianapolis, Indiana.
PRINCETON, N.J., June 8, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that results from an ongoing clinical study of ADXS-HER2 in canine osteosarcoma (OSA), were presented by principal investigator ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced that CEO Dan O'Connor will present at the 2015 Jefferies Global Healthcare Conference on June 1, 2015 at 2 p.m. in New York, NY. Click to read the full press release: http://bit.ly/1SnPDRL
PRINCETON, N.J., May 22, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the 2015 Jefferies Global Healthcare ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has appointed former Director, Global Regulatory Strategy at Bristol-Myers Squibb, Fred J. Frullo, as our VP, Regulatory Affairs. "Over the past 12 months, Advaxis has significantly expanded and accelerated its clinical development activities requiring an individual of Fred's expertise and experience to manage our regulatory processes," said CMO David Mauro. Find out more: http://bit.ly/1HvMqcH
Former Director, Global Regulatory Strategy for Bristol-Myers Squibb. PRINCETON, N.J., May 21, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Fred J. Frullo as Vice President, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis welcomed Thomas W. Hare as the Company's new Vice President, Clinical Operations. As the former Vice President, Drug Development Operations for Incyte Corp., Mr. Hare will oversee clinical operations for Advaxis's multiple Lm-LLO cancer immunotherapy clinical programs. Mr. Hare brings more than 28 years of experience in the biopharmaceutical and contract research organization industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups. http://bit.ly/1EgAbfV
Former Vice President, Drug Development Operations for Incyte Corp. and Clinical Manager/Senior Scientist for Bristol-Myers Squibb to Spearhead Advaxis's Clinical Operations as Company Advances Multiple Clinical Programs. PRINCETON, N.J., May 6, 2015 (GLOBE NEWSWIRE) -- Advaxis, ...
1
Add a comment...
People
Have them in circles
27 people
Calvin Nokes's profile photo
Jeff Anlauf's profile photo
Giovanna Beeney's profile photo
David Miller's profile photo
Rick Vandewaa's profile photo
Jason Ian Hector's profile photo
Bettina Lau's profile photo
jim dooley's profile photo
Brad Loncar's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.